Verastem (VSTM)
(Delayed Data from NSDQ)
$3.36 USD
+0.38 (12.75%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $3.40 +0.04 (1.19%) 7:46 PM ET
4-Sell of 5 4
F Value F Growth A Momentum F VGM
Brokerage Reports
Verastem, Inc. [VSTM]
Reports for Purchase
Showing records 101 - 120 ( 266 total )
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Retail Sales Tracker for Hem. Malignancies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended May 8
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Copiktra Sales Picking up Steam; Higher $3.00 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended April 24
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
A Potential Path to Approval in Ovarian Cancer; Lung Results Await Clarity; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended March 13
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
New Strategy Bolstered by Strong Balance Sheet; Higher $2.75 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended January 24 2020
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Promising Combination Results in New License Agreement; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Retail Sales Tracker for Hem. Malignancies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Retail Sales Tracker for Hem. Malignancies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Promising Clinical Updates at ASH; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
First Steps on the Long Road to Profitability; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
New Management Outlines Copiktra Strategy; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
We are placing shares of VSTM Under Review, and transferring coverage to Jerry Isaacson, Ph.D. due to the departure of the covering analyst.
Provider: Roth Capital Partners, Inc.
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Coverage Update - Healthcare Sector
Provider: Roth Capital Partners, Inc.
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
A Disappointing Quarter for Copiktra; Lowering PT to $2.50; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S